Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07555301

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

An observational study tracking the clinical course of patients with IgA nephropathy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

IgA Nephropathy (IgAN) Autoimmune Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Glomerulonephritis, IGA Immune System Diseases Kidney Diseases Male Urogenital Diseases Nephritis Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • IgA Nephropathy, Use of Sparsentan

Exclusion criteria

  • age < 18y

Treatment and study plan

Sparsentan

Drug

Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

Primary outcomes

  1. Change of Albuminuria

    Time frame: 36 months

    What is the impact of sparsentan on Albuminuria

Study contacts

Contact information is provided by the study sponsor or research team.

Andi Schleich

CONTACT

[email protected]

+41 44 416 21 55

Sponsors and collaborators

Lead sponsor

Waid City Hospital, Zurich

Other

Registry information

Acronym: SWIAN

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Apr 29, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.